Literature DB >> 28630710

HDAC Inhibitor Conjugated Polymeric Prodrug Micelles for Doxorubicin Delivery.

Suchithra A Senevirathne1, Katherine E Washington1, Jason B Miller2, Michael C Biewer1, David Oupicky3, Daniel J Siegwart2, Mihaela C Stefan1.   

Abstract

Amphiphilic diblock copolymers bearing histone deacetylase inhibitors (HDACi) (4-phenyl butyric acid and valproic acid) were synthesized by the ring-opening polymerization of γ-4-phenylbutyrate-ε-caprolactone (PBACL), γ-valproate-ε-caprolactone (VPACL), and ε-caprolactone (CL) from a poly(ethylene glycol) macroinitiator (PEG). These amphiphilic diblock copolymers self-assembled into stable pro-drug micelles and demonstrated excellent biocompatibility. High loading of doxorubicin (DOX) up to 5.1 wt% was achieved. Optimized micelles enabled sustained drug release in a concentration-dependent manner over time to expand the therapeutic window of cytotoxic small molecule drugs.

Entities:  

Year:  2017        PMID： 28630710      PMCID： PMC5473365          DOI： 10.1039/C6TB03038F

Source DB:  PubMed          Journal:  J Mater Chem B        ISSN： 2050-750X            Impact factor:   6.331


  21 in total

Review 1.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.

Authors:  H Maeda
Journal:  Adv Enzyme Regul       Date:  2001

2.  Polymer micelles with crystalline cores for thermally triggered release.

Authors:  Amanda L Glover; Sarah M Nikles; Jacqueline A Nikles; Christopher S Brazel; David E Nikles
Journal:  Langmuir       Date:  2012-07-11       Impact factor: 3.882

Review 3.  Histone deacetylase HDAC1/HDAC2-controlled embryonic development and cell differentiation.

Authors:  Reinhard Brunmeir; Sabine Lagger; Christian Seiser
Journal:  Int J Dev Biol       Date:  2009       Impact factor: 2.203

Review 4.  Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery.

Authors:  Julien Nicolas; Simona Mura; Davide Brambilla; Nicolas Mackiewicz; Patrick Couvreur
Journal:  Chem Soc Rev       Date:  2013-02-07       Impact factor: 54.564

Review 5.  Design of polymeric nanoparticles for biomedical delivery applications.

Authors:  Mahmoud Elsabahy; Karen L Wooley
Journal:  Chem Soc Rev       Date:  2012-02-14       Impact factor: 54.564

6.  Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.

Authors:  Jeffrey Hrkach; Daniel Von Hoff; Mir Mukkaram Ali; Elizaveta Andrianova; Jason Auer; Tarikh Campbell; David De Witt; Michael Figa; Maria Figueiredo; Allen Horhota; Susan Low; Kevin McDonnell; Erick Peeke; Beadle Retnarajan; Abhimanyu Sabnis; Edward Schnipper; Jeffrey J Song; Young Ho Song; Jason Summa; Douglas Tompsett; Greg Troiano; Tina Van Geen Hoven; Jim Wright; Patricia LoRusso; Philip W Kantoff; Neil H Bander; Christopher Sweeney; Omid C Farokhzad; Robert Langer; Stephen Zale
Journal:  Sci Transl Med       Date:  2012-04-04       Impact factor: 17.956

7.  Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors.

Authors:  Qiang Lu; Da-Sheng Wang; Chang-Shi Chen; Yuan-Dong Hu; Ching-Shih Chen
Journal:  J Med Chem       Date:  2005-08-25       Impact factor: 7.446

8.  Preparation and characterization of poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA) microspheres for controlled release of paclitaxel.

Authors:  Gang Ruan; Si-Shen Feng
Journal:  Biomaterials       Date:  2003-12       Impact factor: 12.479

Review 9.  Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.

Authors:  Aleksey G Kazantsev; Leslie M Thompson
Journal:  Nat Rev Drug Discov       Date:  2008-10       Impact factor: 84.694

10.  Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways.

Authors:  Suwei Wang; Eugene A Konorev; Srigiridhar Kotamraju; Joy Joseph; Shasi Kalivendi; B Kalyanaraman
Journal:  J Biol Chem       Date:  2004-03-30       Impact factor: 5.157
View more
  3 in total

1.  Histone Deacetylase Inhibitor (HDACi) Conjugated Polycaprolactone for Combination Cancer Therapy.

Authors:  Ruvanthi N Kularatne; Katherine E Washington; Chandima Bulumulla; Erika L Calubaquib; Michael C Biewer; David Oupicky; Mihaela C Stefan
Journal:  Biomacromolecules       Date:  2018-02-27       Impact factor: 6.988

2.  Reduction-responsive PEtOz-SS-PCL micelle with tailored size to overcome blood-brain barrier and enhance doxorubicin antiglioma effect.

Authors:  Yuling Li; Li Baiyang; Bu Leran; Wang Zhen; Xie Yandong; Du Baixiang; Zhu Dandan; Zhu Yufu; Liang Jun; Yu Rutong; Liu Hongmei
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

3.  Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer.

Authors:  Wu Chen; Danlei Yu; Shi-Yong Sun; Feng Li
Journal:  Acta Biomater       Date:  2021-05-25       Impact factor: 10.633
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.